NEW YORK, Jan. 26, 2022 /PRNewswire/ -- The Gross Law
Firm, securities class action litigators, issues the following
notice to shareholders of Reata Pharmaceuticals, Inc.
Shareholders who purchased or otherwise acquired Reata
securities, and/or sold Reata put options, between
November 9, 2020 and
December 8, 2021 are
encouraged to contact the firm regarding possible lead plaintiff
appointment. Appointment as lead plaintiff is not required to
partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/reata-pharmaceuticals-inc-loss-submission-form-2/?id=22515&from=4
ALLEGATIONS: The complaint alleges that during the
class period, Defendants issued materially false and/or misleading
statements and/or failed to disclose that: (1) the Food and Drug
Administration had raised concerns regarding the validity of the
clinical study designed to measure the efficacy and safety of
bardoxolone for the treatment of chronic kidney disease caused by
Alport syndrome; (2) as a result, there was a material risk that
Reata's New Drug Application would not be approved; and (3) as a
result of the foregoing, defendants' positive statements about the
Company's business, operations, and prospects were materially
misleading and/or lacked a reasonable basis.
DEADLINE FEBRUARY 18,
2022: Shareholders should not delay in registering
for this class action. Register your information here:
https://securitiesclasslaw.com/securities/reata-pharmaceuticals-inc-loss-submission-form-2/?id=22515&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of RETA during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. There is no cost or obligation to you to
participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm's mission is to
protect the rights of all investors who have suffered as the result
of deceit, fraud, and illegal business practices. The Gross Law
Firm is committed to ensuring that companies adhere to responsible
business practices and engage in good corporate citizenship. Our
team puts in the work to get the maximum recovery on behalf of
investors. Attorney advertising. Prior results do not guarantee
similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original
content:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-reata-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-february-18-2022--reta-301469079.html
SOURCE The Gross Law Firm